support_agent

Your contact persons

CHEPLAPHARM Arzneimittel GmbH

View:
format_list_bulletedgrid_view

01/05/2021

CHEPLAPHARM completes it´s largest acquisition so far
Investors Domain
Read morechevron_right

01/05/2021

CHEPLAPHARM completes it´s largest acquisition so far
Press releases
Read morechevron_right

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets
Investors Domain
Read morechevron_right

01/04/2021

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets
Press releases
Read morechevron_right

12/21/2020

CHEPLAPHARM donates over €200,000 for Christmas
Press releases
Read morechevron_right

12/16/2020

CHEPLAPHARM proves its vigour
Investors Domain
Read morechevron_right

12/16/2020

CHEPLAPHARM proves its vigour
Press releases
Read morechevron_right

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition
Press releases
Read morechevron_right

11/02/2020

CHEPLAPHARM closes another product portfolio acquisition
Archive Investor Relations Investors Domain
Read morechevron_right

10/15/2020

CHEPLAPHARM succeeds again: 1 Billion Euros (equivalent) of Senior Secured Notes placed with institutional Investors

CHEPLAPHARM Arzneimittel GmbH has successfully gained a foothold in the US American institutional bond market.


Investor Relations Archive
Read morechevron_right
Back to topexpand_less